PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
0.02%
Cash & equivalents changing 0.02% while CRVO's remains stable. Warren Buffett would analyze the strategic implications of this divergence.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Higher Cash + Short-Term Investments Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Higher Total Current Assets Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Higher Total Assets Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
Less than half of CRVO's 3144.16%. David Dodd sees a more disciplined short-term liability approach.
14.30%
Higher Long-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.30%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
13.25%
Less than half of CRVO's 3635.03%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.27%
Below half CRVO's 15.68%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
41.19%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-16.23%
Below half CRVO's -344.69%. Michael Burry sees potential underperformance in building shareholder capital.
0.02%
Higher Liabilities + Equity Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
14.30%
Less than half of CRVO's 3215.72%. David Dodd sees less overall debt expansion vs. competitor.
17.98%
Less than half of CRVO's 3215.46%. David Dodd sees better deleveraging or stronger cash buildup than competitor.